Argos Therapeutics, Inc. Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
3/4/2013 11:28:51 AM
DURHAM, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced it has validated the durability of the immune response for metastatic renal cell carcinoma (mRCC) patients treated with AGS-003. Additionally, the Company confirmed the correlation between specific immune markers and overall survival in these patients is statistically significant. The data from these studies will be presented during two poster sessions at Keystone Symposia's Understanding Dendritic Cell Biology to Advanced Diseases Therapies Conference on March 3-8 in Keystone, Colorado.
comments powered by